EClinicalMedicineJul 1, 2026

Weight loss and heart health after metabolic surgery with incretin-based treatments in the US

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 2, 2026

Abstract

Weight loss and major adverse cardiovascular events were evaluated in individuals who underwent metabolic and bariatric surgery and received incretin-based therapy.

Metabolic and bariatric surgery (MBS) is commonly associated with challenges in long-term weight management.
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1RA) may serve as helpful adjunctive therapies following MBS.
The impact of incretin-based therapy on weight loss and major adverse cardiovascular events (MACE) in this population is of growing interest.

Simplified

Long-term weight management after metabolic and bariatric surgery (MBS) remains a prevalent clinical challenge. Given the efficacy of glucagon-like peptide-1 receptor (GLP-1RA) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1RA), there is increasing interest in their role as adjunctive therapy after MBS. We examined weight loss and major adverse cardiovascular events (MACE) in people who underwent MBS and subsequently received incretin-based therapy.

Full Text

Full text is available at the source.

View Full Text ↗

Featured in

GLP-1 Therapies

GLP-1 TherapiesIssue #44

Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

what lands in your inbox each week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study

Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients

1 week ago7 studies

Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group

2 weeks ago8 studies

New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients

3 weeks ago7 studies

GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery

4 weeks ago7 studies

Semaglutide linked to reduced cigarette craving in 24 smokers

5 weeks ago7 studies

Two-thirds of patients kept weight off after stopping GLP-1 drugs

6 weeks ago7 studies

Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months

8 weeks ago7 studies

Semaglutide linked to 2.5x higher risk of sudden vision loss

9 weeks ago7 studies

Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial

10 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief